JP2015501291A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501291A5 JP2015501291A5 JP2014532118A JP2014532118A JP2015501291A5 JP 2015501291 A5 JP2015501291 A5 JP 2015501291A5 JP 2014532118 A JP2014532118 A JP 2014532118A JP 2014532118 A JP2014532118 A JP 2014532118A JP 2015501291 A5 JP2015501291 A5 JP 2015501291A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- antibody
- fusion protein
- protein according
- regions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161539416P | 2011-09-26 | 2011-09-26 | |
| US61/539,416 | 2011-09-26 | ||
| PCT/US2012/057393 WO2013049254A1 (en) | 2011-09-26 | 2012-09-26 | Hybrid constant regions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501291A JP2015501291A (ja) | 2015-01-15 |
| JP2015501291A5 true JP2015501291A5 (enExample) | 2015-11-19 |
| JP6205363B2 JP6205363B2 (ja) | 2017-09-27 |
Family
ID=47996377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014532118A Active JP6205363B2 (ja) | 2011-09-26 | 2012-09-26 | ハイブリッド定常領域 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8952134B2 (enExample) |
| EP (1) | EP2760891B1 (enExample) |
| JP (1) | JP6205363B2 (enExample) |
| CN (1) | CN103974977A (enExample) |
| CA (1) | CA2849765C (enExample) |
| WO (1) | WO2013049254A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9382319B2 (en) | 2011-09-26 | 2016-07-05 | Jn Biosciences Llc | Hybrid constant regions |
| CA2849765C (en) | 2011-09-26 | 2021-10-19 | Jn Biosciences Llc | Hybrid constant regions |
| CA2872908C (en) | 2012-05-10 | 2023-11-14 | Gerhard Frey | Multi-specific monoclonal antibodies |
| WO2014022592A1 (en) * | 2012-08-02 | 2014-02-06 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece |
| US20150038682A1 (en) * | 2013-08-02 | 2015-02-05 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via homomultimerizing peptide |
| CA2922830A1 (en) * | 2013-09-05 | 2015-04-16 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
| TW201619188A (zh) * | 2014-03-05 | 2016-06-01 | 優稀美生物醫藥公司 | 多聚體Ｆｃ蛋白質 |
| JP6851199B2 (ja) * | 2014-03-05 | 2021-03-31 | ユーシービー バイオファルマ エスアールエル | 多量体Ｆｃタンパク質 |
| US10280208B2 (en) | 2014-04-30 | 2019-05-07 | Albert Einstein College Of Medicine | TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| EP3750918A1 (en) * | 2015-01-20 | 2020-12-16 | IGM Biosciences, Inc. | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
| JP6882184B2 (ja) * | 2015-03-25 | 2021-06-02 | アイジーエム バイオサイエンシズ インコーポレイテッド | 多価ｂ型肝炎ウイルス抗原結合分子およびその使用 |
| MX2017012805A (es) * | 2015-04-07 | 2018-04-11 | Genentech Inc | Complejo de unión a antígenos con actividad agonista y métodos de uso. |
| WO2016168758A1 (en) | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| GB201515745D0 (en) * | 2015-09-04 | 2015-10-21 | Ucb Biopharma Sprl | Proteins |
| JP2019511458A (ja) * | 2016-01-27 | 2019-04-25 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 組み換えＩｇＧ Ｆｃ多量体 |
| US20190330360A1 (en) * | 2016-07-20 | 2019-10-31 | Igm Biosciences, Inc. | Multimeric gitr binding molecules and uses thereof |
| US11401337B2 (en) * | 2017-04-07 | 2022-08-02 | Igm Biosciences, Inc. | Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function |
| US11542330B2 (en) * | 2017-05-08 | 2023-01-03 | Adimab, Llc | Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use |
| US20200392239A1 (en) * | 2018-02-26 | 2020-12-17 | Igm Biosciences, Inc. | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
| US12060419B2 (en) | 2018-06-14 | 2024-08-13 | Regeneron Pharmaceuticals, Inc. | CD79A chimeric antigen receptors |
| KR20210009421A (ko) | 2018-06-14 | 2021-01-26 | 바이오아트라, 엘엘씨 | 다중 특이적 항체 구조체 |
| KR20210083260A (ko) * | 2018-10-23 | 2021-07-06 | 아이쥐엠 바이오사이언스 인코포레이티드 | 다가 IgM- 및 IgA-Fc 기반 결합 분자 |
| CA3115547A1 (en) * | 2018-11-14 | 2020-05-22 | Jn Biosciences Llc | Multimeric hybrid fc proteins for replacement of ivig |
| JP7774447B2 (ja) | 2019-06-07 | 2025-11-21 | アディマブ・リミテッド・ライアビリティ・カンパニー | 高アフィニティ抗ｃｄ３抗体、ならびにその作製方法及び使用方法 |
| EP3983445A4 (en) * | 2019-06-14 | 2023-06-21 | 2seventy bio, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER |
| EP4130047A4 (en) * | 2020-02-27 | 2024-07-31 | Huahui Health Ltd. | SOLUBLE ACE2 AND FUSION PROTEIN AND THEIR USES |
| WO2022080912A1 (ko) * | 2020-10-16 | 2022-04-21 | 주식회사 아이엠바이오로직스 | IgM 영역을 이용한 융합단백질 플랫폼 |
| MX2023015461A (es) * | 2021-06-17 | 2024-01-18 | Fapon Biotech Inc | Inmunoglobulina quimerica. |
| KR20240034234A (ko) | 2021-07-14 | 2024-03-13 | 2세븐티 바이오, 인코포레이티드 | 항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체 |
| CN119546327A (zh) | 2022-04-08 | 2025-02-28 | 再生元制药公司 | 多部分受体和信号传导复合物 |
| WO2024196707A2 (en) * | 2023-03-17 | 2024-09-26 | The Board Of Trustees Of The University Of Illinois | Chimeric antibody molecules based on tetrameric teleost immunoglobulin m |
| EP4606901A1 (en) * | 2024-01-02 | 2025-08-27 | Gempharmatech Co., Ltd | Animal model for producing humanized antibody, and construction method therefor |
| KR20250173023A (ko) * | 2024-05-30 | 2025-12-10 | 주식회사 아이엠바이오로직스 | J 사슬에 연결되는 링커 및 이를 포함하는 j 사슬 복합체 |
| CN119638846B (zh) * | 2025-01-09 | 2025-11-04 | 康复大学青岛中心医院 | uMtCK抗体或其抗原结合片段 |
| CN121405821A (zh) * | 2025-12-30 | 2026-01-27 | 山东大学 | 一种融合蛋白及在制备治疗或预防乙肝病毒产品中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8719963D0 (en) * | 1987-08-24 | 1987-09-30 | Cattaneo A | Recombinant dna products |
| DE10001372A1 (de) * | 2000-01-14 | 2001-08-02 | Deutsches Krebsforsch | Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen |
| US7951378B2 (en) * | 2000-04-28 | 2011-05-31 | Planet Biotechnology Inc. | Immunoadhesin comprising a chimeric ICAM-1 molecule produced in a plant |
| US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2433877C (en) * | 2001-01-17 | 2014-11-18 | Aptevo Research And Development Llc | Binding domain-immunoglobulin fusion proteins |
| KR100900176B1 (ko) * | 2001-03-07 | 2009-06-02 | 메르크 파텐트 게엠베하 | 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술 |
| AU2004289820A1 (en) * | 2003-11-13 | 2005-05-26 | Dsm Ip Assets B.V. | Use of a vulcanised thermoplastic elastomer or styrene-ethylene-butadiene-styrene polymer as infill material in artificial turf systems |
| CN101778867A (zh) * | 2007-06-08 | 2010-07-14 | 地中海大学 | 用于治疗胰腺肿瘤的组合物和方法 |
| CA2849765C (en) | 2011-09-26 | 2021-10-19 | Jn Biosciences Llc | Hybrid constant regions |
-
2012
- 2012-09-26 CA CA2849765A patent/CA2849765C/en active Active
- 2012-09-26 CN CN201280047037.9A patent/CN103974977A/zh active Pending
- 2012-09-26 EP EP12836751.3A patent/EP2760891B1/en active Active
- 2012-09-26 US US13/627,929 patent/US8952134B2/en active Active
- 2012-09-26 JP JP2014532118A patent/JP6205363B2/ja active Active
- 2012-09-26 WO PCT/US2012/057393 patent/WO2013049254A1/en not_active Ceased
-
2014
- 2014-11-17 US US14/543,845 patent/US20150073130A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015501291A5 (enExample) | ||
| JP2015524821A5 (enExample) | ||
| JP7790754B2 (ja) | Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用 | |
| SI2699264T1 (en) | Antibodies and other molecules that bind b7-h1 and pd-1 | |
| TWI899079B (zh) | 抗ror1/抗cd3雙特異性結合分子 | |
| CA2929256C (en) | Production of t cell retargeting hetero-dimeric immunoglobulins | |
| HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
| JP2020508655A5 (enExample) | ||
| JP2023528036A (ja) | Ｔｉｇｉｔに対する抗体 | |
| EP4464333A3 (en) | Anti-death receptor antibodies and methods of use thereof | |
| HRP20192346T1 (hr) | Molekule anti-lag-3 antitijela i njihove uporabe | |
| RU2018142544A (ru) | Биспецифические связывающие белки и пути их применения | |
| EA202092460A1 (ru) | Антитела к ox40 и способы применения | |
| JP2019513817A (ja) | Ｔｉｇｉｔに対する抗体 | |
| HRP20240415T1 (hr) | Kimerni antigenski receptori antigena kapa mijeloma i njihova upotreba | |
| JP2019536470A5 (enExample) | ||
| CN109862910A (zh) | 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效 | |
| JP2019524693A5 (enExample) | ||
| JP2021516952A (ja) | 新規な抗体分子、その調製方法及びその使用 | |
| HRP20180937T1 (hr) | Poboljšavanje transporta terapijskih molekula kroz krvno-moždanu barijeru | |
| JP2018525999A5 (enExample) | ||
| JP2019513725A5 (enExample) | ||
| KR20180095086A (ko) | 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체 | |
| JP2016507523A5 (enExample) | ||
| BR112019024419A2 (pt) | anticorpos compreendendo regiões constantes pesadas modificadas |